Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Francesco Maura, Eileen M Boyle, Benjamin Diamond, Patrick Blaney, Hussein Ghamlouch, Bachisio Ziccheddu, Yubao Wang, Kylee H Maclachlan, James E. Hoffman, Hani Hassoun, Sham Mailankody, Urvi A Shah, Carlyn Tan, Malin Hultcrantz, Michael Scordo, Dickran Kazandjian, Gunjan L Shah, Heather J Landau, David J. Chung, Sergio Giralt, Benedetto Bruno, Yanming Zhang, Arnaldo A Arbini, Ahmet Dogan, Alexander Lesokhin, Faith E Davies, Neha Korde, Gareth J Morgan, Ola Landgren
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200360295